Kymera Therapeutics (NASDAQ:KYMR) rose ~16% in after-hours trading Friday after the company announced it would release phase 1 data of its inflammatory diseases oral candidate KT-621 in healthy ...

Interleukin (IL)-1 is a prototypic proinflammatory cytokine. It is produced by numerous cell types (i.e., macrophages, synoviocytes, endothelial cells, chondrocytes, osteoclasts) and is found in ...

The first direct and selective interleukin-1 (IL-1) receptor antagonist, anakinra can be used alone or in combination with any of the other DMARDs, except those in the tumor necrosis factor (TNF ...

SAN DIEGO -- Patients with moderate to severe ulcerative colitis experienced clinical, endoscopic, histological, and biological improvements with the first-in-class interleukin (IL)-7 receptor ...

Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...

Key predictors of chronic pain following motor vehicle collisions include elevated levels of acute post-traumatic stress ...